Market LIVE
Published markets; coverage varies by country
Product profile · United States

SCEMBLIX

 ·  Patent Litigation & Settlement History ↓

IngredientASCIMINIB HYDROCHLORIDE
Application typeNDA
Application215358
Product002
Dosage formTABLET
RouteORAL
StrengthEQ 40MG BASE
Approval date2021-10-29
Marketing statusPrescription
Status event—
ApplicantNOVARTIS
Product source

Current GenericRadar decision

Year2035
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2035-10-29
Patent anchor2035-10-29
Exclusivity anchor2028-10-29
Protection date2040-05-17
First Final ANDA—
Status event—

POST_ANCHOR_RIGHTS_REMAIN; canonical=2035-10-29; exact Final ANDA not directly identified; not generic absence; USER_DECISION_REQUIRED applied current best classification

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
88291952035-10-29DS/U U-1374YNTRUE_DS
| B1C0201 issued-claim review2026-10-14: TRUE_DS
———
88291952035-10-29ORANGE_BOOK U-1374YNTRUE_DS
English description not available.
———
114077352040-05-14DS —NNOTHER
| B1C0201 issued-claim review2026-10-14: OTHER
———
114077352040-05-14ORANGE_BOOK —NNOTHER
English description not available.
———
122524782040-05-14DP —NNDP
| B1C0201 issued-claim review2026-10-14: DP
———
122524782040-05-14ORANGE_BOOK —NNDP
English description not available.
———
122524792040-05-17U U-1374NNU
| B1C0201 issued-claim review2026-10-14: U
———
122524792040-05-17ORANGE_BOOK U-1374NNU
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2021-10-292026-10-29English description not available.YY2026-10-29—Source
NCE2021-10-292026-10-29English description not available.YY2026-10-29Source
I-9532024-10-292027-10-29English description not available.NN——Source
I-9532024-10-292027-10-29English description not available.NN—Source
I-9542024-10-292027-10-29English description not available.NN——Source
I-9542024-10-292027-10-29English description not available.NN—Source
M-3182025-10-022028-10-02English description not available.NN——Source
M-3182025-10-022028-10-02English description not available.NN—Source
ODE-3812021-10-292028-10-29English description not available.NN——Source
ODE-3812021-10-292028-10-29English description not available.NN—Source
ODE-3822021-10-292028-10-29English description not available.NN——Source
ODE-3822021-10-292028-10-29English description not available.NN—Source
ODE-4992024-10-292031-10-29English description not available.NN——Source
ODE-4992024-10-292031-10-29English description not available.NN—Source
ODE-5002024-10-292031-10-29English description not available.NN——Source
ODE-5002024-10-292031-10-29English description not available.NN—Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (13)
TypeDateRoleBasisSource
PATENT2035-10-29CANONICAL_ANCHOREnglish description not available.Source
PATENT2040-05-14FTO_TAILEnglish description not available.Source
PATENT2040-05-14FTO_TAILEnglish description not available.Source
PATENT2040-05-17FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2035-10-29CANONICAL_DECISIONPOST_ANCHOR_RIGHTS_REMAIN; canonical=2035-10-29; exact Final ANDA not directly identified; not generic absence; USER_DECISION_REQUIRED applied current best classificationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.